EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects

Samuel A Blackman, Ahlam N Qerqez, Alison G Lee, Nicole V Johnson, Justin M Owens, Grace S Lai, Emma C Aldrich, Kayla G Sprenger, Jangsoon Lee, Sophie Verrier, Martin J Stoddart, Annalee W Nguyen und 1 weitere

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.111476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Samuel A Blackman und 12 weiteren Autor:innen. Beteiligte Einrichtung: McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas, USA. Hauptthemen laut MEDLINE: Neuropilin-1, Vascular Endothelial Growth Factor A, Placenta Growth Factor, Antibodies. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation, The Welch Foundation, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies blocking the function of vascular endothelial growth factor A (VEGFA) remain a promising therapeutic strategy, especially when combined with check-point inhibitors, but their efficacy is limited by tumor resistance. This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). The activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To address this, we aimed to discover new antibodies with precision blockade of PlGF-2 or VEGFA binding to NRP1 in the presence of heparin that complement existing resources to probe PlGF and VEGFA biology. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model. By contrast, antibodies binding PlGF-2 or VEGFA to block NRP1 significantly reduced proliferation and migration of Caki-I kidney carcinoma cells in vitro, indicating this receptor mediates additional effects. Interestingly, one antibody exhibited dual-reactive binding to VEGFA and PlGF-2, suggesting a novel therapeutic strategy to prevent PlGF-driven VEGF-resistance. Overall, these antibodies define new mechanisms to disrupt PlGF activity and support a role for NRP1 in cell proliferation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuropilin-1Vascular Endothelial Growth Factor APlacenta Growth FactorAntibodiesHumansCell ProliferationHuman Umbilical Vein Endothelial CellsVascular Endothelial Growth Factor Receptor-1

Stichwörter der Autor:innen

NRP1PlGFVEGFVEGFR1angiogenesisantibodyheparinphage display

Substanzen

Neuropilin-1Vascular Endothelial Growth Factor APlacenta Growth FactorPGF protein, humanVEGFA protein, humanNRP1 protein, humanVascular Endothelial Growth Factor Receptor-1Antibodies

Autor:innen und Institutionen

  • McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas, USA.
  • Interdisciplinary Life Sciences Graduate Program, The University of Texas at Austin, Austin, Texas, USA.
  • Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, Colorado, USA.
  • University of Hawaii Comprehensive Cancer Center, University of Hawaii, Honolulu, Hawaii, USA.
  • AO Research Institute Davos, Davos, Switzerland.
  • McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas, USA. Electronic address: nguyen@che.utexas.edu.

Förderung

  • National Science Foundation
  • The Welch Foundation
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Blackman, S. A., Qerqez, A. N., Lee, A. G., Johnson, N. V., Owens, J. M., Lai, G. S., Aldrich, E. C., Sprenger, K. G., Lee, J., Verrier, S., Stoddart, M. J., Nguyen, A. W., & Maynard, J. A. (2026). Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111476

Vancouver

Blackman SA, Qerqez AN, Lee AG, Johnson NV, Owens JM, Lai GS, et al. Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111476

BibTeX
@article{Blackman2026,
  author = {Blackman, Samuel A and Qerqez, Ahlam N and Lee, Alison G and Johnson, Nicole V and Owens, Justin M and Lai, Grace S and Aldrich, Emma C and Sprenger, Kayla G and Lee, Jangsoon and Verrier, Sophie and Stoddart, Martin J and Nguyen, Annalee W and Maynard, Jennifer A},
  title = {Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.111476}
}
Kostenlos starten →